Increases in C-reactive protein may predict recurrence of clozapine-induced fever

Annals of Pharmacotherapy

Volumn 43, Issue 1, 2009, Pages 143-146

  Konen, Izchak ^a,b,c   Afzal, Noman ^a   Hussain, Saira ^a   Manu, Peter ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Northwell Health   (United States)

Author keywords

C reactive protein; Clozapine; Immunomodulatory

Indexed keywords

C REACTIVE PROTEIN; CLOZAPINE; CYTOKINE; INTERLEUKIN 6; LORAZEPAM; QUETIAPINE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ACUTE PHASE RESPONSE; AGED; ARTICLE; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CASE REPORT; DEMENTIA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEVER; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEWY BODY; MALE; NARANJO PROBABILITY SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RATING SCALE; RECURRENCE RISK; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; METABOLISM; PREDICTIVE VALUE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLOZAPINE; FEVER; HUMANS; MALE; PREDICTIVE VALUE OF TESTS;

EID: 58549111991     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L467     Document Type: Article

References (20)

1. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-90.
2. Lowe CM, Grube RRA, Scates AC. Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 2007;41:1700-4. Epub 4 Sept 2007. DOI 10.1345/aph.1K126
3. Jeong SH, Ahn YM, Koo YJ. The characteristics of clozapine-induced fever. Schizophr Res 2002;56:191-3.
4. Nittenson NC, Kando JC, Frakenburg FR, et al. Fever associated with Clozapine administration (letter). Am J Psychiatry 1995;152:1102.
5. Tham JC, Dickson RA. Clozapine-induced fevers and 1-year discontinuation rate. J Clin Psychiatry 2002;63:880-4.
6. Gerson SL. G-CSF and the management of clozapine induced agranulocytosis. J Clin Psychiatry 1994;55:139-42.
7. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
8. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1998;24:25-9.
9. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6.
10. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999;33:623-30. DOI 10.1345/aph.18216
11. Maes M, Bosmans E, Kenis G, et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26:221-5.
12. Kluger MJ. Fever: role of pyogens and cryogens. Physiol Rev 1991;71:93-117.
13. Gudewill S, Pollmacher T, Vedder H. Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992;242:53-6.
14. Smith RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992;39:248-57.
15. Ganguli R, Yang Z, Shurin G. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994;51:1-10.
16. Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokines and soluble cytokine receptor levels. J Clin Psychopharmacol 1996;16:403-9.
17. Tremeau F, Clark SC, Printz D, et al. Spiking fevers with clozapine treatment. Clin Neuropharmacol 1997;20:168-70.
18. Druss BG, Mazure CM. Transient fever and hematologic abnormalities during clozapine use. J Clin Psychopharmacol 1993;13:155-6.
19. De Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1059-63.
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.